Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Actinium is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Type
Public
HQ
New York, US
Founded
2000
Size (employees)
23 (est)
Actinium Pharmaceuticals was founded in 2000 and is headquartered in New York, US
Report incorrect company information

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, US (HQ)
275 Madison Ave
Show all (1)
Report incorrect company information

Actinium Pharmaceuticals Financials and Metrics

Actinium Pharmaceuticals Financials

USD

Net income (Q2, 2017)

(7.1 m)

EBIT (Q2, 2017)

(7.2 m)

Market capitalization (18-Apr-2018)

24.9 m

Cash (30-Jun-2017)

11.5 m
Actinium Pharmaceuticals's current market capitalization is $24.9 m.
Annual
USDFY, 2014FY, 2016

General and administrative expense

10.2 m9.3 m

R&D expense

12.3 m

Operating expense total

22.4 m9.3 m

EBIT

(22.5 m)(26.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

830.7 k1.7 m2.4 m3.3 m3.8 m3.6 m1.8 m2.2 m2.8 m1.4 m3.3 m2.8 m

Operating expense total

1.6 m4.1 m4.4 m7 m7.9 m7.4 m4.6 m6 m6.9 m7.1 m7.8 m7.2 m

EBIT

(1.6 m)(4.1 m)(4.4 m)(7 m)(7.9 m)(7.4 m)(4.6 m)(6 m)(6.9 m)(7.1 m)(7.8 m)(7.2 m)

Interest expense

1.3 k5.7 k1.6 k588 2.7 k1.7 k666
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

5.5 m6.7 m25.6 m20.5 m

Accounts Receivable

2.1 b

Inventories

218.4 k699.9 k803.5 k1.8 m

Current Assets

5.8 m7.4 m26.5 m22.4 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

26 m24.8 m22.2 m20.5 m15.5 m17.1 m11.5 m

Current Assets

26.2 m24.9 m23.2 m21.4 m17.1 m18.1 m12.5 m

PP&E

86.2 k95.3 k115.6 k110 k91.2 k75.9 k70 k

Total Assets

26.3 m25 m23.3 m21.6 m17.3 m18.2 m13 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.8 m)(24.7 m)(21 m)(24.3 m)

Depreciation and Amortization

1.6 k37.9 k53.5 k77.5 k

Inventories

106.6 k(193.9 k)162.1 k(1 m)

Accounts Payable

(793.9 k)2.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(4.9 m)(16.7 m)(13.2 m)(19.3 m)(3.1 m)(10.5 m)(14.5 m)(4.4 m)(11 m)(17.6 m)(8.1 m)(15.1 m)

Depreciation and Amortization

1.4 k9.5 k23.8 k10.4 k26.6 k43.4 k18.1 k37.6 k57.7 k20.9 k35.3 k

Accounts Payable

236.3 k666.5 k1.4 m(1 m)(1.3 m)(1.4 m)378.9 k(94.8 k)1.1 m573.9 k(590.3 k)

Cash From Operating Activities

(4.9 m)(2.5 m)(5.1 m)(9.3 m)(5.8 m)(11.1 m)(14.6 m)(4.8 m)(11 m)(16.5 m)(5.4 m)(12.5 m)
USDY, 2017

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information